|
|
| |
 |
|
|
|
|
 |
|
Breast Cancer Recurrence Testing
|
 |
Clinical Significance
It is estimated that 210,000 women will develop breast cancer each year. Approximately 43% are ER positive, node negative with a disease free five year survival of 87%. Increased survival with cytotoxic chemotherapy for a small subset of patients has been shown. Clinicians and patients are faced with difficult choices as to whether to add toxic adjuvant chemotherapy in addition to standard endocrine treatment. Mammostrat can help clinicians understand the inherent aggressiveness of the tumor and the likelihood of tumor recurrence.
Indication for Use
Mammostrat is a tool designed to assess the biologic aggressiveness of a breast cancer specimen. Based upon testing results, patients are classified as having a relatively low, moderate, or high risk of breast cancer recurrence. The assay is intended to aid in the selection of the appropriate therapeutic management for the patient.
Highlights
- A five biomarker-based assay targeted specifically to the most poorly differentiated areas of invasive tumor.
- The results of each stain are entered into an algorithm which computes a Risk Index (RI) and classifies a patient into a risk category of low, moderate, or high-risk of recurrence.
- Mammostrat markers are independent of proliferation markers and hormone receptors. Along with a morphological assessment of tumor and traditional prognostic features (ER, PR, HER2), the complete pathologic classification of the tumor tissue, including risk stratification is available early in the diagnostic work up.
- Mammostrat can be performed on either core or excisional specimen. Additional testing is recommended on the excisional sample if morphologies between the two specimens are inconsistent.
|
|
|
|
 |
|
 |
|
|
|
|
|
| |
|